Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ongoing BEACON Phase 1/2 ...

Women with amnestic mild cognitive impairment and early Alzheimer’s disease had lower levels of acetyl-L-carnitine and its ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time.